X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Drug Nod Delays Not Hampering South Korean Pharma Position

Content Team by Content Team
1st February 2023
in Drug Development, News

According to a survey from Fitch Solutions, South Korea’s pharmaceutical market attractiveness is expected to stay strong despite ongoing concerns about the country’s slow pace of drug authorizations.

According to the analysis, the pharmaceutical business will remain competitive due to high per-capita spending on drugs and a highly creative R&D environment.

Fitch stated that the government’s support for the pharmaceutical industry, as demonstrated by the recent announcement of new legislation to improve medicine accessibility, will be beneficial for South Korea’s long-term potential as an attractive proposition for pharmaceutical firms.

Pharmaceutical sales are expected to expand at a 4.3% compound annual growth rate (CAGR) in local market terms, growing from KRW28.5 trillion in 2022 to KRW35.3 trillion by 2027, according to Fitch. It equates to a $32.1 billion gain overall.

It has been suggested that the predicted extension of the schedule for pharmaceutical approval in South Korea is likely to continue.

According to the Ministry of Food and Drug Safety (MFDS), the review length for 235 medications licensed in South Korea between 2011 and 2020 climbed to 353 days in 2020 from 276 days in 2011, as per a research study completed in 2022 by the Korea Research-based Pharma Industry Association (KRPIA).

The US Food and Drug Administration, European Medicines Agency, and Japan’s Pharmaceuticals and Medical Devices Agency have decreased the timeframe for new drug approval and review by ten, five, and three days, respectively, between 2011 and 2020.

According to Fitch, patients in South Korea continue to be at a disadvantage in terms of the number of novel medications available, although gradual improvements will continue to close the gap.

Despite this, it is anticipated that South Korea will persist in upholding applicable regulations to augment the availability of medication and guarantee that progressive products are suitably appraised.

In November 2022, the South Korean Ministry of Food and Drug Safety (MFDS) declared the commencement of a new program, known as Global Innovative Products on Fast Track (GIFT), which is analogous to the breakthrough therapy designation system of the United States Food and Drug Administration (FDA).

In the span of two years, the Korean Fast Track system has granted expedited authorization to more than 20 medications, among them being treatments for the orphan, cancer, and COVID-19 diseases, as reported by Fitch.

Previous Post

In-Person Meetings To Begin By The FDA Starting February 13

Next Post

UK Into Thailand Genomic Collaboration On Health Threats

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post

UK Into Thailand Genomic Collaboration On Health Threats

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In